The Enigmatic Threat of Marburg Virus in Kenya's Kitum Cave

Mount Elgon National Park in Kenya harbours a notorious landmark – Kitum Cave.

This cavern has gained its dark fame after two visitors succumbed to a deadly virus known as Marburg. Studies suggest that the virus lurks in caves and mines frequented by bats, particularly those belonging to the Rousettus colony. Prolonged exposure to such environments can be risky as evidenced by the tragic fates of a French man in 1980 and a young boy from France in 1987. Both individuals died shortly after visiting Kitum Cave, exhibiting symptoms characteristic of Marburg virus infection.

This strong correlation led many to believe the virus was the culprit. The United States Army Medical Research Institute of Infectious Disease (USAMRIID) launched a meticulous investigation at the cave to shed light on these deaths. However, their findings were perplexing – no trace of the Marburg virus was detected. This contradicted the initial assumptions about the cause of death. Despite these inconclusive results, Kitum Cave retains its reputation as one of the world's most perilous caves.

Marburg virus, previously known as Marburg Hemorrhagic Fever, is a highly lethal pathogen. Primarily harboured by bats, it can spread from these creatures to humans through close contact. The virus has an incubation period of two to nine days during which individuals are not contagious. Once the virus takes hold, symptoms like severe headache, chills, and fever begin to manifest. As the disease progresses, a horrifying rash erupts across the chest and back. Jaundice, bleeding, and significant weight loss are also common. In the most severe cases, multi-organ failure can occur.

Recent cases of Marburg virus have emerged in South Africa, with the patient having a travel history to Zimbabwe. Other parts of Africa, including Angola, Kenya, and the Democratic Republic of Congo (DRC), have also grappled with outbreaks of this terrifying virus. Marburg virus disease (MVD) remains a serious public health threat globally. Central Africa bears the brunt of this zoonotic illness with periodic outbreaks and a concerningly high fatality rate exceeding 88%. Uganda, for instance, witnessed MVD cases in 2012 and 2014.

The World Health Organization (WHO) acknowledges the heightened risk of MVD transmission within affected countries but downplays the likelihood of a global pandemic. Collaborative efforts are underway between the WHO and health ministries in affected regions. These initiatives focus on bolstering various response measures including disease surveillance, laboratory capacity building, patient management protocols, risk communication, infection prevention and control practices, and fostering community engagement. In response to the resurgence of MVD in Africa, the Centers for Disease Control and Prevention (CDC) has issued targeted travel advisories for impacted countries.

These advisories vary in severity based on the specific circumstances. Importantly, the CDC does not advocate for broader international travel or trade restrictions at this time. This measured approach is informed by experience managing similar outbreaks in the past. MVD shares clinical characteristics and transmission pathways with the Ebola virus. Consequently, similar infection prevention and control strategies, such as safe burial practices are paramount in curbing the spread of both diseases.